{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:13:54Z","timestamp":1790374434201,"version":"4.1.0"},"reference-count":117,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:p>Access to high-quality reproductive health care is important for adolescents and young adults with HIV infection to prevent unintended pregnancies, sexually transmitted infections, and secondary transmission of HIV to partners and children. As perinatally HIV-infected children mature into adolescence and adulthood and new HIV infections among adolescents and young adults continue to occur in the United States, medical providers taking care of such individuals often face issues related to sexual and reproductive health. Challenges including drug interactions between several hormonal methods and antiretroviral agents make decisions regarding contraceptive options more complex for these adolescents. Dual protection, defined as the use of an effective contraceptive along with condoms, should be central to ongoing discussions with HIV-infected young women and couples wishing to avoid pregnancy. Last, reproductive health discussions need to be integrated with discussions on HIV care, because a reduction in plasma HIV viral load below the level of detection (an \u201cundetectable viral load\u201d) is essential for the individual\u2019s health as well as for a reduction in HIV transmission to partners and children.<\/jats:p>","DOI":"10.1542\/peds.2016-1892","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T09:07:25Z","timestamp":1472461645000},"source":"Crossref","is-referenced-by-count":10,"title":["Contraception for HIV-Infected Adolescents"],"prefix":"10.1542","volume":"138","author":[{"given":"Athena P.","family":"Kourtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COMMITTEE ON PEDIATRIC AIDS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","reference":[{"issue":"4","key":"2022072515380972300_B1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2014-2300","article-title":"Contraception for adolescents.","volume":"134","author":"Ott","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"2022072515380972300_B2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.AOG.0000433993.07969.e8","article-title":"Committee Opinion No. 572: reproductive health care for adolescents with human immunodeficiency virus.","volume":"122","author":"American College of Obstetricians and Gynecologists","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2022072515380972300_B3","unstructured":"Centers for Disease Control and Prevention\n          . HIV Surveillance Report. February 2015. Available at: www.cdc.gov\/hiv\/library\/reports\/surveillance\/. Accessed January 4, 2016"},{"key":"2022072515380972300_B4","unstructured":"Centers for Disease Control and Prevention\n          . Estimated HIV incidence in the United States, 2007\u20132010. HIV Surveillance Supplemental Report. 2012;17(4). Available at: www.cdc.gov\/hiv\/pdf\/statistics_hssr_vol_17_no_4.pdf. Accessed January 4, 2016"},{"key":"2022072515380972300_B5","unstructured":"Centers for Disease Control and Prevention\n          . New HIV infections in the United States. Available at: www.cdc.gov\/nchhstp\/newsroom\/\/docs\/2012\/HIV-Infections-2007-2010.pdf. Accessed January 4, 2016"},{"key":"2022072515380972300_B6","unstructured":"Centers for Disease Control and Prevention\n          . HIV among Youth. Available at: www.cdc.gov\/hiv\/risk\/age\/youth\/index.html?s_cid=tw_std0141316. Accessed January 4, 2016"},{"issue":"47","key":"2022072515380972300_B7","first-page":"971","article-title":"Vital signs: HIV infection, testing, and risk behaviors among youths\u2014United States.","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"2022072515380972300_B8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/apc.2011.0025","article-title":"Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment.","volume":"25","author":"Mellins","year":"2011","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"2022072515380972300_B9","first-page":"1","article-title":"Youth risk behavior surveillance\u2014United States, 2013.","volume":"63","author":"Kann","year":"2014","journal-title":"MMWR Suppl"},{"issue":"4","key":"2022072515380972300_B10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jpepsy\/jsu103","article-title":"Substance use and the development of sexual risk behaviors in youth perinatally exposed to HIV.","volume":"40","author":"Elkington","year":"2015","journal-title":"J Pediatr Psychol"},{"issue":"3","key":"2022072515380972300_B11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0000000000000054","article-title":"Unplanned pregnancies among HIV-infected women in care-United States.","volume":"65","author":"Sutton","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"2022072515380972300_B12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/QAI.0000000000000014","article-title":"Pregnancy intentions among women living with HIV in the United States.","volume":"65","author":"Rahangdale","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022072515380972300_B13","unstructured":"Centers for Disease Control and Prevention\n          . HIV among pregnant women, infants, and children. Available at: www.cdc.gov\/hiv\/risk\/gender\/pregnantwomen\/facts\/index.html. Accessed January 4, 2016"},{"issue":"1","key":"2022072515380972300_B14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10461-011-9906-1","article-title":"Discussing childbearing with HIV-infected women of reproductive age in clinical care: a comparison of Brazil and the US.","volume":"16","author":"Finocchario-Kessler","year":"2012","journal-title":"AIDS Behav"},{"issue":"8","key":"2022072515380972300_B15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2105\/AJPH.2013.301265","article-title":"Engaging HIV care providers in conversations with their reproductive-age patients about fertility desires and intentions: a historical review of the HIV epidemic in the United States.","volume":"103","author":"Steiner","year":"2013","journal-title":"Am J Public Health"},{"issue":"3","key":"2022072515380972300_B16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/QAI.0b013e3182167dec","article-title":"Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006.","volume":"57","author":"Whitmore","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"2022072515380972300_B17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10995-012-1070-3","article-title":"Reproductive health decision-making in perinatally HIV-infected adolescents and young adults.","volume":"17","author":"Fair","year":"2013","journal-title":"Matern Child Health J"},{"issue":"11","key":"2022072515380972300_B18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/apc.2014.0162","article-title":"Providers caring for adolescents with perinatally- acquired HIV: current practices and barriers to communication about sexual and reproductive health.","volume":"28","author":"Albright","year":"2014","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"2022072515380972300_B19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/apc.2009.0293","article-title":"Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring?","volume":"24","author":"Finocchario-Kessler","year":"2010","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"2022072515380972300_B20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1542\/peds.2013-1073","article-title":"Transitioning HIV-infected youth into adult health care.","volume":"132","author":"Committee on Pediatric Aids","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"2022072515380972300_B21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1542\/peds.2011-0969","article-title":"Supporting the health care transition from adolescence to adulthood in the medical home.","volume":"128","author":"Cooley","year":"2011","journal-title":"Pediatrics"},{"issue":"7","key":"2022072515380972300_B22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/apc.2012.0041","article-title":"\u201cIt\u2019s like losing a part of my family\u201d: transition expectations of adolescents living with perinatally acquired HIV and their guardians.","volume":"26","author":"Fair","year":"2012","journal-title":"AIDS Patient Care STDS"},{"issue":"6","key":"2022072515380972300_B23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jadohealth.2013.07.006","article-title":"Neurocognitive functioning in antiretroviral therapy-na\u00efve youth with behaviorally acquired human immunodeficiency virus.","volume":"53","author":"Nichols","year":"2013","journal-title":"J Adolesc Health"},{"key":"2022072515380972300_B24","doi-asserted-by":"crossref","first-page":"18593","DOI":"10.7448\/IAS.16.1.18593","article-title":"Understanding the mental health of youth living with perinatal HIV infection: lessons learned and current challenges.","volume":"16","author":"Mellins","year":"2013","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"2022072515380972300_B25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/heapol\/czt043","article-title":"Integrating family planning services into HIV care and treatment clinics in Tanzania: evaluation of a facilitated referral model.","volume":"29","author":"Baumgartner","year":"2014","journal-title":"Health Policy Plan"},{"key":"2022072515380972300_B26","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/heapol\/czh046","article-title":"HIV\/AIDS, sexual and reproductive health: intersections and implications for national programmes.","volume":"19","author":"Berer","year":"2004","journal-title":"Health Policy Plan"},{"issue":"1","key":"2022072515380972300_B27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/09540121.2014.954982","article-title":"Providers\u2019 perspectives on male involvement in family planning in the context of a cluster-randomized controlled trial evaluating integrating family planning into HIV care in Nyanza Province, Kenya.","volume":"27","author":"Tao","year":"2015","journal-title":"AIDS Care"},{"key":"2022072515380972300_B28","unstructured":"Centers for Disease Control and Prevention\n          . Preconception health and health care: my reproductive life plan. Available at: www.cdc.gov\/preconception\/documents\/reproductivelifeplan-worksheet.pdf. Accessed January 4, 2016"},{"key":"2022072515380972300_B29","unstructured":"Guttmacher Institute\n          . State policies in brief: an overview of Minors' Consent Law. Available at: www.guttmacher.org\/statecenter\/spibs\/spib_OMCL.pdf. Accessed January 4, 2016"},{"key":"2022072515380972300_B30","unstructured":"Guttmacher Institute\n          . State policies in brief: minors' access to STI services. Available at: www.guttmacher.org\/statecenter\/spibs\/spib_MASS.pdf. Accessed January 4, 2016"},{"issue":"2","key":"2022072515380972300_B31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jadohealth.2014.11.001","article-title":"State policy and teen childbearing: a review of research studies.","volume":"56","author":"Beltz","year":"2015","journal-title":"J Adolesc Health"},{"key":"2022072515380972300_B32","volume-title":"Pediatrics","author":"Committee on Adolescent Health; Committee on Psychosocial Aspects of Child and Family Health","year":"2004"},{"issue":"2","key":"2022072515380972300_B33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1054-139X(04)00086-2","article-title":"Confidential health care for adolescents: position paper for the Society for Adolescent Medicine.","volume":"35","author":"Ford","year":"2004","journal-title":"J Adolesc Health"},{"key":"2022072515380972300_B34","doi-asserted-by":"crossref","unstructured":"American Medical Association\n          . The AMA code of medical ethics\u2019 opinion on confidential services for children and adolescents. AMA J Ethics. 2012;14:778\u2013779. Available at: http:\/\/journalofethics.ama-assn.org\/2012\/10\/coet1-1210.html. Accessed January 4, 2016","DOI":"10.1001\/virtualmentor.2012.14.10.coet1-1210"},{"key":"2022072515380972300_B35","article-title":"US Selected Practice Recommendations for Contraceptive Use.","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"2022072515380972300_B36","first-page":"193","article-title":"Contraceptive implants","volume-title":"Contraceptive Technology","author":"Raymond","year":"2011","edition":"revised ed."},{"issue":"3","key":"2022072515380972300_B37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/AOG.0000000000000690","article-title":"Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.","volume":"125","author":"McNicholas","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2022072515380972300_B38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.contraception.2009.12.006","article-title":"Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy.","volume":"81","author":"Lewis","year":"2010","journal-title":"Contraception"},{"issue":"5","key":"2022072515380972300_B39","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.fertnstert.2008.02.140","article-title":"Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.","volume":"91","author":"Darney","year":"2009","journal-title":"Fertil Steril"},{"issue":"1","key":"2022072515380972300_B40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/humrep\/15.1.118","article-title":"Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception.","volume":"15","author":"Beerthuizen","year":"2000","journal-title":"Hum Reprod"},{"issue":"3","key":"2022072515380972300_B41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijgo.2010.01.018","article-title":"Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years.","volume":"109","author":"Pongsatha","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"2022072515380972300_B42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/QAD.0000000000000177","article-title":"Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.","volume":"28","author":"Perry","year":"2014","journal-title":"AIDS"},{"issue":"5","key":"2022072515380972300_B43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/17425255.2013.772579","article-title":"Drug interactions between antiretrovirals and hormonal contraceptives.","volume":"9","author":"Tseng","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2022072515380972300_B44","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/137192","article-title":"Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and efavirenz","author":"Carten","year":"2012","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"4","key":"2022072515380972300_B45","doi-asserted-by":"crossref","first-page":"19484","DOI":"10.7448\/IAS.17.4.19484","article-title":"Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.","volume":"17","author":"Scarsi","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2022072515380972300_B46","author":"Scarsi"},{"key":"2022072515380972300_B47","unstructured":"US Agency for International Development\n          . Drug interactions between hormonal contraceptive methods and anti-retroviral medications used to treat HIV. Technical Issue Brief; October 2014:1\u20134. Available at: www.cdc.gov\/globalaids\/resources\/pmtct-care\/docs\/hc_art-brief_final.pdf. Accessed January 4, 2016"},{"issue":"4","key":"2022072515380972300_B48","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/QAI.0000000000000189","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV- positive women.","volume":"66","author":"Vieira","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"2022072515380972300_B49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijgo.2011.12.002","article-title":"Safety and efficacy of contraceptive implants for HIV-infected women in Porto Alegre, Brazil.","volume":"117","author":"Kreitchmann","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"2022072515380972300_B50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.contraception.2011.09.005","article-title":"Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz.","volume":"85","author":"Leticee","year":"2012","journal-title":"Contraception"},{"key":"2022072515380972300_B51","unstructured":"HIVInfo.\n          Guidelines on Antiretroviral Use Among Women. Table 3: Drug Interactions Between Antiretroviral Agents and Hormonal Contraceptives. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/table\/table-3-drug-interactions-between-antiretroviral-agents-and-hormonal-contraceptives. Accessed February 19, 2022"},{"key":"2022072515380972300_B52","unstructured":"National Institutes of Health\n          . Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed January 4, 2016"},{"key":"2022072515380972300_B53","unstructured":"World Health Organization\n          . Medical eligibility criteria for contraceptive use. 5th ed. Executive summary. Geneva, Switzerland: World Health Organization; 2015. Available at: www.who.int\/reproductivehealth\/publications\/family_planning\/Ex-Summ- MEC-5\/en\/. Accessed January 4, 2016"},{"key":"2022072515380972300_B54","article-title":"Centers for Disease Control and Prevention. US Medical Eligibility Criteria (US MEC) for Contraceptive Use.","year":"2016"},{"key":"2022072515380972300_B55","first-page":"147","article-title":"Intrauterine contraceptives (IUCs)","volume-title":"Contraceptive Technology","author":"Deans","year":"2011","edition":"ed."},{"key":"2022072515380972300_B56","unstructured":"Centers for Disease Control and Prevention\n          . U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep. 2013;62(RR-5):1\u201346. Available at: www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6205a1.htm. Accessed January 4, 2016"},{"key":"2022072515380972300_B57","unstructured":"Bayer HealthCare Pharmaceuticals\n          . Skyla [package insert]. 2013. Available at: http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Skyla_PI.pdf. Accessed January 4, 2016"},{"key":"2022072515380972300_B58","unstructured":"Bayer HaelthCare Pharmaceuticals Inc\n          . Mirena [package insert]. 2014. Available at: http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Mirena_PI.pdf. Accessed January 4, 2016"},{"key":"2022072515380972300_B59","unstructured":"Teva Women's Health I. ParaGuard T 380A [package insert]. 2013. Available at: www.paragard.com\/Pdf\/ParaGard-PI.pdf. Accessed January 4, 2016"},{"issue":"8","key":"2022072515380972300_B60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1056\/NEJMoa010438","article-title":"Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women.","volume":"345","author":"Hubacher","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2022072515380972300_B61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.contraception.2005.08.007","article-title":"Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review.","volume":"73","author":"Mohllajee","year":"2006","journal-title":"Contraception"},{"issue":"8796","key":"2022072515380972300_B62","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/0140-6736(92)91904-M","article-title":"Intrauterine devices and pelvic inflammatory disease: an international perspective.","volume":"339","author":"Farley","year":"1992","journal-title":"Lancet"},{"issue":"2","key":"2022072515380972300_B63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/jwh.2013.4556","article-title":"U.S. selected practice recommendations for contraceptive use, 2013.","volume":"23","author":"Tepper","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"key":"2022072515380972300_B64","article-title":"Safety of intrauterine devices among womenwith HIV: a systematic review [published online ahead of print June 22, 2016].","author":"Tepper","journal-title":"Contraception"},{"issue":"11","key":"2022072515380972300_B65","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1093\/humrep\/del264","article-title":"The levonorgestrel- releasing intrauterine system (LNG-IUS) in HIV-infected women\u2014 effects on bleeding patterns, ovarian function and genital shedding of HIV.","volume":"21","author":"Heikinheimo","year":"2006","journal-title":"Hum Reprod"},{"issue":"1","key":"2022072515380972300_B66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.contraception.2006.09.006","article-title":"Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women.","volume":"75","author":"Lehtovirta","year":"2007","journal-title":"Contraception"},{"issue":"2","key":"2022072515380972300_B67","doi-asserted-by":"crossref","first-page":"126.e1","DOI":"10.1016\/j.ajog.2010.09.002","article-title":"The levonorgestrel-releasing intrauterine system in human immunodeficiency virus- infected women: a 5-year follow-up study.","volume":"204","author":"Heikinheimo","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2022072515380972300_B68","doi-asserted-by":"crossref","first-page":"e1001778","DOI":"10.1371\/journal.pmed.1001778","article-title":"Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.","volume":"12","author":"Morrison","year":"2015","journal-title":"PLoS Med"},{"issue":"2","key":"2022072515380972300_B69","doi-asserted-by":"crossref","first-page":"144.e1","DOI":"10.1016\/j.ajog.2007.03.031","article-title":"A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus.","volume":"197","author":"Stringer","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"2022072515380972300_B70","unstructured":"Pfizer. Depo-provera CI [package insert]. 2010. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020246s036lbl.pdf. Accessed January 4, 2016"},{"issue":"2","key":"2022072515380972300_B71","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.contraception.2009.02.001","article-title":"Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception.","volume":"80","author":"Beksinska","year":"2009","journal-title":"Contraception"},{"issue":"4","key":"2022072515380972300_B72","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.contraception.2014.07.009","article-title":"Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.","volume":"90","author":"Polis","year":"2014","journal-title":"Contraception"},{"issue":"5","key":"2022072515380972300_B73","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/QAD.0b013e32835bb672","article-title":"Effect of hormonal contraceptive methods on HIV disease progression: a systematic review.","volume":"27","author":"Phillips","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"2022072515380972300_B74","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.fertnstert.2007.07.1348","article-title":"Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy.","volume":"90","author":"Nanda","year":"2008","journal-title":"Fertil Steril"},{"issue":"2","key":"2022072515380972300_B75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.clpt.6100040","article-title":"Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.","volume":"81","author":"Cohn","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2022072515380972300_B76","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.10.002","article-title":"Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.","volume":"77","author":"Watts","year":"2008","journal-title":"Contraception"},{"key":"2022072515380972300_B77","doi-asserted-by":"crossref","first-page":"18575","DOI":"10.7448\/IAS.16.1.18575","article-title":"Bone health in children and adolescents with perinatal HIV infection.","volume":"16","author":"Puthanakit","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"2022072515380972300_B78","first-page":"249","article-title":"Combined oral contraceptives","volume-title":"Contraceptive Technology.","author":"Nelson","year":"2011"},{"issue":"6","key":"2022072515380972300_B79","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jpag.2007.06.001","article-title":"Adolescent and young women\u2019s experience with the vaginal ring and oral contraceptive pills.","volume":"20","author":"Stewart","year":"2007","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"2","key":"2022072515380972300_B80","doi-asserted-by":"crossref","first-page":"e2020007237","DOI":"10.1542\/peds.2020-007237","article-title":"Barrier protection use by adolescents during sexual activity.","volume":"146","author":"Grubb LK; American Academy of Pediatrics, Committee on Adolescence","year":"2020","journal-title":"Pediatrics"},{"issue":"3","key":"2022072515380972300_B81","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/AOG.0b013e3181cf45dc","article-title":"Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial.","volume":"115","author":"Gilliam","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2022072515380972300_B82","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/01.AOG.0000228850.85346.e2","article-title":"Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population.","volume":"108","author":"Bakhru","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2022072515380972300_B83","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e3182a9b3f1","article-title":"Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.","volume":"65","author":"Atrio","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"2022072515380972300_B84","first-page":"1","article-title":"Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006-2010 national survey of family growth.","author":"Martinez","year":"2011","journal-title":"Vital Health Stat 23"},{"key":"2022072515380972300_B85","first-page":"371","article-title":"Male condoms","volume-title":"Contraceptive Technology","author":"Warner","year":"2011"},{"key":"2022072515380972300_B86","unstructured":"Centers for Disease Control and Prevention\n          . Condom fact sheet in brief. Available at: www.cdc.gov\/condomeffectiveness\/docs\/condomfactsheetinbrief.pdf. Accessed January 4, 2016"},{"issue":"6","key":"2022072515380972300_B87","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1542\/peds.2012-2962","article-title":"Emergency contraception.","volume":"130","author":"Committee on Adolescence","year":"2012","journal-title":"Pediatrics"},{"key":"2022072515380972300_B88","unstructured":"US Food and Drug Administration\n          . FDA approves Plan B One-Step emergency contraceptive for use without a prescription for all women of child-bearing potential [news release]. Silver Spring, MD: US Food and Drug Administration; June 20, 2013. Available at: www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm358082.htm. Accessed January 4, 2016"},{"issue":"10","key":"2022072515380972300_B89","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1473-3099(02)00396-1","article-title":"Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women.","volume":"2","author":"Wilkinson","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"2022072515380972300_B90","first-page":"391","article-title":"Vaginal barriers and spermicides","volume-title":"Contraceptive Technology","author":"Cates","year":"2011","edition":"revised ed."},{"key":"2022072515380972300_B91","author":"US Agency for International Development","year":"2013"},{"issue":"3","key":"2022072515380972300_B92","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1086\/519432","article-title":"The influence of hormonal contraceptive use on HIV-1 transmission and disease progression.","volume":"45","author":"Baeten","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2022072515380972300_B93","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0897.2010.00930.x","article-title":"Hormonal contraception and HIV-1 transmission.","volume":"65","author":"Blish","year":"2011","journal-title":"Am J Reprod Immunol"},{"issue":"6","key":"2022072515380972300_B94","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.contraception.2010.10.008","article-title":"Low-dose combined oral contraceptive and cervicovaginal shedding of human immunodeficiency virus.","volume":"83","author":"Roccio","year":"2011","journal-title":"Contraception"},{"issue":"9082","key":"2022072515380972300_B95","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0140-6736(97)04240-2","article-title":"Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina.","volume":"350","author":"Mostad","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"2022072515380972300_B96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1473-3099(11)70247-X","article-title":"Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.","volume":"12","author":"Heffron","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2022072515380972300_B97","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0b013e32835ad539","article-title":"Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence.","volume":"27","author":"Polis","year":"2013","journal-title":"AIDS"},{"issue":"22","key":"2022072515380972300_B98","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1001\/jama.1993.03500220046024","article-title":"Detection of HIV DNA in cervical and vaginal secretions: prevalence and correlates among women in Nairobi, Kenya.","volume":"269","author":"Clemetson","year":"1993","journal-title":"JAMA"},{"issue":"9293","key":"2022072515380972300_B99","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(01)06653-3","article-title":"Determinants of HIV-1 shedding in the genital tract of women.","volume":"358","author":"Kovacs","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"2022072515380972300_B100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00002030-200401230-00009","article-title":"The effect of hormonal contraception on genital tract shedding of HIV-1.","volume":"18","author":"Wang","year":"2004","journal-title":"AIDS"},{"key":"2022072515380972300_B101","unstructured":"World Health Organization\n          . Hormonal contraceptive methods for women at high risk of HIV and living with HIV. 2014 Guidance statement. Geneva, Switzerland: World Health Organization; 2014. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/128537\/1\/WHO_ RHR_14.24_eng.pdf?ua=1. Accessed January 4, 2016"},{"issue":"2","key":"2022072515380972300_B102","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5414\/CP201943","article-title":"Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.","volume":"52","author":"Crauwels","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"2022072515380972300_B103","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/QAI.0b013e31827e8f98","article-title":"Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.","volume":"62","author":"Landolt","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"2022072515380972300_B104","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00042560-200204150-00007","article-title":"Pharmacokinetic interaction between nevirapine and ethinyl estradiol\/ norethindrone when administered concurrently to HIV-infected women.","volume":"29","author":"Mildvan","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022072515380972300_B105","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/QAD.0000000000000050","article-title":"Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness.","volume":"27","author":"Nanda","year":"2013","journal-title":"AIDS"},{"issue":"2","key":"2022072515380972300_B106","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/QAI.0b013e31822b8bf8","article-title":"Combined oral contraceptives and antiretroviral PK\/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi.","volume":"58","author":"Stuart","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"2022072515380972300_B107","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3851\/IMP1725","article-title":"The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.","volume":"16","author":"Sevinsky","year":"2011","journal-title":"Antivir Ther"},{"issue":"1","key":"2022072515380972300_B108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.contraception.2009.01.009","article-title":"Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.","volume":"80","author":"Sch\u00f6ller-Gy\u00fcre","year":"2009","journal-title":"Contraception"},{"issue":"18","key":"2022072515380972300_B109","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1097\/QAD.0000000000000493","article-title":"Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.","volume":"28","author":"Heffron","year":"2014","journal-title":"AIDS"},{"issue":"3","key":"2022072515380972300_B110","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.contraception.2014.10.008","article-title":"Sino-implant (II)\u00ae continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.","volume":"91","author":"Todd","year":"2015","journal-title":"Contraception"},{"issue":"6","key":"2022072515380972300_B111","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/aji.12210","article-title":"Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.","volume":"71","author":"Thurman","year":"2014","journal-title":"Am J Reprod Immunol"},{"issue":"6","key":"2022072515380972300_B112","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.contraception.2012.05.001","article-title":"Effect of injectable contraceptive use on response to antiretroviral therapy among women in Rakai, Uganda.","volume":"86","author":"Polis","year":"2012","journal-title":"Contraception"},{"issue":"9","key":"2022072515380972300_B113","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/aje\/kwi116","article-title":"Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy.","volume":"161","author":"Chu","year":"2005","journal-title":"Am J Epidemiol"},{"key":"2022072515380972300_B114","doi-asserted-by":"crossref","first-page":"18448","DOI":"10.7448\/IAS.16.1.18448","article-title":"Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in Kenya.","volume":"16","author":"Hubacher","year":"2013","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"2022072515380972300_B115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.hivar.2011.05.002","article-title":"Hormonal contraceptive use and response to antiretroviral therapy among adolescent females","volume":"10","author":"Johnson","year":"2011","journal-title":"HIV and AIDS Review"},{"key":"2022072515380972300_B116","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.antiviral.2013.09.030","article-title":"Multipurpose prevention technologies: products in development.","volume":"100","author":"Friend","year":"2013","journal-title":"Antiviral Res"},{"issue":"1","key":"2022072515380972300_B117","first-page":"CD007006","article-title":"Abstinence-plus programs for HIV infection prevention in high-income countries.","author":"Underhill","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1892\/1339325\/peds_20161892.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1892\/1339325\/peds_20161892.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T15:39:40Z","timestamp":1658763580000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/138\/3\/e20161892\/52716\/Contraception-for-HIV-Infected-Adolescents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":117,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-1892","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]},"article-number":"e20161892"}}